American Epilepsy Society 2025 Annual Meeting, December 5 – 9, Atlanta, Conference Coverage

Opto-Dravet: A Rapid, On-Demand Screening Platform for Therapies in Genetic Epilepsy

Researchers at The Children’s Hospital of Philadelphia have developed a novel screening platform called Opto-Dravet to rapidly test potential therapies for Dravet syndrome, a severe genetic form of epilepsy. Traditional drug screening for Dravet syndrome relies on inducing seizures in mice through elevated temperatures, but this approach has limitations in understanding the cellular mechanisms and may not accurately represent spontaneous seizures that occur in adult patients.

The Opto-Dravet platform uses optogenetics, a technique that employs light to control genetically modified neurons. Scientists created the model by breeding mice with light-sensitive proteins in their neurons with mice carrying the Scn1a gene mutation associated with Dravet syndrome. Adult mice were implanted with optical fibers targeting the hippocampus and electrodes to monitor brain activity. Blue light pulses delivered through the fibers could reliably trigger seizures on demand.

The platform demonstrated impressive reliability, with seizure induction rates of 98% or higher across six tested animals. The optogenetically induced seizures closely resembled spontaneous seizures in their duration and how they spread through the brain. Importantly, the method proved safe, with mortality rates below 1% per stimulation.

When testing established epilepsy medications, the platform accurately predicted their clinical effectiveness. Diazepam and valproate significantly reduced seizure probability and severity, while levetiracetam showed mixed results on seizure induction but reduced behavioral severity. Carbamazepine, known to be ineffective or potentially harmful in Dravet syndrome, showed no beneficial effect in the model, validating the platform’s translational relevance.

This approach offers several advantages over traditional methods: it allows for rapid, repeatable testing within the same animal, can generate detailed pharmacodynamic profiles showing how drugs work over time, and could be adapted for other genetic epilepsies. The researchers suggest this platform could accelerate the discovery and benchmarking of new therapies for Dravet syndrome and related conditions.

In Vivo Adenine Base Editing Rescues Dravet Syndrome in Mice

Researchers from Children’s Hospital of Philadelphia, Harvard University, and collaborating institutions have achieved a significant breakthrough in treating Dravet syndrome by directly correcting the genetic mutation that causes the disorder. This research represents a fundamental shift from symptom management to addressing the root cause of this devastating epilepsy syndrome.

Dravet syndrome results from loss-of-function mutations in the SCN1A gene, which provides instructions for making a voltage-gated sodium channel protein called Nav1.1. One recurrent mutation, R613X, creates a premature stop signal in the gene. The research team used adenine base editing, a precise genome editing technique that can change single DNA letters without cutting the DNA strand, to correct this specific mutation.

The scientists delivered the base editing system to newborn mice using a dual adeno-associated virus approach. This method packages the editing components into viral vectors that can efficiently reach brain cells. The treatment demonstrated remarkable efficiency, correcting 59% of genomic DNA and an impressive 97% of messenger RNA in mouse brains.

The molecular correction translated into meaningful functional improvements. Brain slice studies showed that parvalbumin-expressing GABAergic inhibitory neurons, which are particularly affected in Dravet syndrome, regained normal electrical excitability and action potential properties after treatment. These neurons play crucial roles in preventing excessive brain activity and seizures.

Most importantly, the gene editing therapy rescued key features of the disease in mice. Treated animals were protected against temperature-sensitive seizures, one of the hallmark features of Dravet syndrome. The therapy also dramatically improved survival, with mice living to at least postnatal day 45, whereas untreated Dravet syndrome mice typically die much earlier.

This proof-of-concept study demonstrates that precision genome editing can directly address the underlying genetic cause of Dravet syndrome rather than merely managing symptoms. The findings suggest potential pathways for developing curative treatments for Dravet syndrome and other genetic neurodevelopmental disorders, though considerable work remains before human clinical applications become possible.